Drug intelligence / Profile preview

[203Pb]VMT01

Development stage: Phase 1
Lead developer: Perspective Therapeutics
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[203Pb]VMT01 is a melanocortin 1 receptor (MC1R) targeted theranostic ligand used as an imaging surrogate for [212Pb]VMT01, which is in clinical development for alpha particle therapy for melanoma. [203Pb]VMT01 is used for patient selection and dosimetry assessments before treatment with the therapeutic [212Pb]VMT01. The drug targets and binds to MC1R, a protein that can be overexpressed in metastatic melanoma tumors. In clinical trials, patients first receive [203Pb]VMT01 as an imaging agent, and those who show positive uptake then proceed to treatment with [212Pb]VMT01.

Other names: VMT-01VMT01VMT 01

Targets

MC1R (Melanocortin Type 1 Receptor)

Beyond the preview

Go deeper on [203Pb]VMT01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [203Pb]VMT01.

Explore the full profile